Body fluids

Plasma Fractionation Market Size To Reach USD 23,006 Million By 2027 at a CAGR of 6.2% - Valuates Reports

Retrieved on: 
Monday, April 5, 2021
Anatomy, Blood, Body fluids, Branches of biology, Fractionation, Medical technology, Transfusion medicine, Blood plasma fractionation, Hematology, Blood plasma, Plasma

The Global Plasma Fractionation Market was valued at USD 18,222 Million in 2019 and is expected to reach USD 23,006 Million by 2027, registering a CAGR of 6.2% from 2020 to 2027.

Key Points: 
  • The Global Plasma Fractionation Market was valued at USD 18,222 Million in 2019 and is expected to reach USD 23,006 Million by 2027, registering a CAGR of 6.2% from 2020 to 2027.
  • The rise in the use of immunoglobulins in various therapeutic areas is expected to drive the growth of plasma fractionation market size.
  • The plasma fractionation market is also growing due to favorable government funding for spreading awareness about the use of plasma-derived products.
  • Thus the rising prevalence of bleeding disorders is expected to drive the plasma fractionation market size.

Spaces Making Up "The Interstitium" Are Connected

Retrieved on: 
Wednesday, March 31, 2021
Branches of biology, Body fluids, Oncology, Cell biology, Extracellular fluid, Interstitial, Invasión, Tissue, Connective tissue

This is the finding of a study published online March 31in Communications Biology, an open access journal of Nature.

Key Points: 
  • This is the finding of a study published online March 31in Communications Biology, an open access journal of Nature.
  • Observing no gaps in the HA throughout all interstitial spaces, the authors concluded that such spaces are continuous, with open channels running through all connective tissues.
  • However, research in the field has shown that early on, such invasion often proceeds without tissue breakdown by enzymes, and could happen instead through pre-existing spaces.
  • Moving forward, the team is also developing techniques to examine the protein content in interstitial spaces to understand whether or not nearby tumors alter interstitial spaces to enable cancer cell movement through them.

The District Hospital Santarém to Adopt Biolog Transfusion Solution to Improve Red Blood Cells Traceability

Retrieved on: 
Monday, March 29, 2021
Technology, Health, Finance, Alternative energy, Energy, Surgery, Professional services, Stem cells, Other Technology, Research, Medical devices, Hospitals, Science, Data management, Transfusion medicine, Blood, Medical specialties, Body fluids, Blood transfusion, Traceability, Transfusion, Transfusion practitioner

The District Hospital of Santarm, a well-recognized healthcare center located in the central region of Portugal, has chosen Biolog Transfusion Solution to optimize its blood components management between its healthcare services and blood transfusion department.

Key Points: 
  • The District Hospital of Santarm, a well-recognized healthcare center located in the central region of Portugal, has chosen Biolog Transfusion Solution to optimize its blood components management between its healthcare services and blood transfusion department.
  • In operation since November 2020, this solution provides real-time traceability to red blood cells, from reception to release for transfusion.
  • The implementation of the Biolog Transfusion Solution proved to be a good tool to improve the traceability of the transfusion process and, consequently, the quality of the service provided by the blood transfusion department.
  • By combining software, equipment, and tags, the modular end-to-end Biolog Transfusion Solution offers traceability of blood components products at every stage of the process.

Grifols fosters world's first scientific journal specialized in blood plasma

Retrieved on: 
Monday, March 8, 2021
Anatomy, Branches of biology, Body fluids, Grifols, IBEX 35, Transfusion medicine, Blood plasma, Peer review, GRF

The international, open access, peer-reviewed journal will publish manuscripts evaluated and vetted by independent experts.

Key Points: 
  • The international, open access, peer-reviewed journal will publish manuscripts evaluated and vetted by independent experts.
  • Grifols, as part of its longstanding commitment to the scientific community, will provide the journal with an educational grant during the next two years to establish the publication as a global source for the scientific knowledge and research accomplishments in plasma science.
  • According to Vctor Grifols Deu, co-CEO of Grfols, "At Grifols we're celebrating the creation of Plasmatology and we believe without a doubt it will accelerate the knowledge and research of proprietary plasma therapeutics."
  • The information included in this document has not been verified nor reviewed by the external auditors of the Grifols group.

Grifols fosters world's first scientific journal specialized in blood plasma

Retrieved on: 
Monday, March 8, 2021
Anatomy, Branches of biology, Body fluids, Grifols, IBEX 35, Transfusion medicine, Blood plasma, Peer review, GRF

The international, open access, peer-reviewed journal will publish manuscripts evaluated and vetted by independent experts.

Key Points: 
  • The international, open access, peer-reviewed journal will publish manuscripts evaluated and vetted by independent experts.
  • Grifols, as part of its longstanding commitment to the scientific community, will provide the journal with an educational grant during the next two years to establish the publication as a global source for the scientific knowledge and research accomplishments in plasma science.
  • According to Vctor Grifols Deu, co-CEO of Grfols, "At Grifols we're celebrating the creation of Plasmatology and we believe without a doubt it will accelerate the knowledge and research of proprietary plasma therapeutics."
  • The information included in this document has not been verified nor reviewed by the external auditors of the Grifols group.

Enzyre announces strategic partnership with Takeda to accelerate development of pioneering diagnostic technology platform for hemophilia patients

Retrieved on: 
Thursday, March 4, 2021
Coagulation system, Blood, Anatomy, Body fluids, Coagulation, Factor VIII, Factor VII, Haemophilia, Factor V, Jeanne Lusher

Takeda confirmed the partnership by investing in Enzyre and joining its supervisory board.

Key Points: 
  • Takeda confirmed the partnership by investing in Enzyre and joining its supervisory board.
  • The Hemophilia Enzycard, the first product using Enzyre's proprietary Enzypad platform technology, can be used to determine the coagulation status of patients with hemophilia, a rare genetic disorder that affects an estimated 400,000 people worldwide.
  • [1] Those with hemophilia lack sufficient blood-clotting proteins, for example factor VIII (FVIII), causing them to bleed for a longer time after an injury compared to people without hemophilia.
  • Enzycard will enable patients to test in a home setting, immediately transferring coagulation status results to the patient's treating physician through a mobile phone app.

Enzyre announces strategic partnership with Takeda to accelerate development of pioneering diagnostic technology platform for hemophilia patients

Retrieved on: 
Thursday, March 4, 2021
Coagulation system, Blood, Anatomy, Body fluids, Coagulation, Factor VIII, Factor VII, Haemophilia, Factor V, Jeanne Lusher

Takeda confirmed the partnership by investing in Enzyre and joining its supervisory board.

Key Points: 
  • Takeda confirmed the partnership by investing in Enzyre and joining its supervisory board.
  • The Hemophilia Enzycard, the first product using Enzyre's proprietary Enzypad platform technology, can be used to determine the coagulation status of patients with hemophilia, a rare genetic disorder that affects an estimated 400,000 people worldwide.
  • [1] Those with hemophilia lack sufficient blood-clotting proteins, for example factor VIII (FVIII), causing them to bleed for a longer time after an injury compared to people without hemophilia.
  • Enzycard will enable patients to test in a home setting, immediately transferring coagulation status results to the patient's treating physician through a mobile phone app.

Haemonetics To Present At The Jefferies Plasma Summit

Retrieved on: 
Friday, February 26, 2021
Anatomy, Branches of biology, Body fluids, Haemonetics, Blood, Hae, Hematology, Blood plasma

BOSTON, Feb. 26, 2021 /PRNewswire/ -- Haemonetics Corporation (NYSE: HAE) announced that Chris Simon, President and CEO, will present at the Jefferies Plasma Summit on Thursday, March 11, 2021, at 10:45 a.m.

Key Points: 
  • BOSTON, Feb. 26, 2021 /PRNewswire/ -- Haemonetics Corporation (NYSE: HAE) announced that Chris Simon, President and CEO, will present at the Jefferies Plasma Summit on Thursday, March 11, 2021, at 10:45 a.m.
  • The public may access Mr. Simon's video presentation live via webcast at: https://wsw.com/webcast/jeff171/hae/1665048 .
  • Haemonetics (NYSE: HAE) is a global healthcare company dedicated to providing a suite of innovative medical products and solutions for customers, to help them improve patient care and reduce the cost of healthcare.
  • Our technology addresses important medical markets: blood and plasma component collection, the surgical suite and hospital transfusion services.

$1.2 Billion Worldwide Animal Blood Plasma Products and Derivatives Industry to 2027 - Impact of COVID-19 on the Market

Retrieved on: 
Thursday, February 25, 2021
Anatomy, Branches of biology, Body fluids, Blood, Blood plasma, Hematology, Transfusion medicine, Derivative

DUBLIN, Feb. 25, 2021 /PRNewswire/ -- The "Animal Blood Plasma Products and Derivatives - Global Market Trajectory & Analytics" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • DUBLIN, Feb. 25, 2021 /PRNewswire/ -- The "Animal Blood Plasma Products and Derivatives - Global Market Trajectory & Analytics" report has been added to ResearchAndMarkets.com's offering.
  • The 143-page report presents concise insights into how the pandemic has impacted production and the buy side for 2020 and 2021.
  • Amid the COVID-19 crisis, the global market for Animal Blood Plasma Products and Derivatives estimated at US$1.2 Billion in the year 2020, is projected to reach a revised size of US$1.8 Billion by 2027, growing at a CAGR of 6.5% over the analysis period 2020-2027.
  • The U.S. Market is Estimated at $343.7 Million, While China is Forecast to Grow at 6.1% CAGR
    The Animal Blood Plasma Products and Derivatives market in the U.S. is estimated at US$343.7 Million in the year 2020.

Cerus Corporation and Shandong Zhongbaokang Medical Implements Partner to Establish Joint Venture in China

Retrieved on: 
Wednesday, February 24, 2021
Other Health, General Health, Pharmaceutical, Oncology, Medical devices, Infectious diseases, Hospitals, Surgery, Cardiology, Biotechnology, Medical Supplies, Health, Branches of biology, Body fluids, Transfusion medicine, Blood, Hematology, Coagulation system, Platelet, Blood cell, Draft:Cerus Corporation

Cerus Corporation (Nasdaq: CERS) and Shandong Zhongbaokang Medical Implements Co. Ltd. (ZBK) today announced that they are forming a joint venture (JV) with the intent to develop, obtain regulatory approval for, manufacture and commercialize the INTERCEPT Blood System for platelets and red blood cells in China.

Key Points: 
  • Cerus Corporation (Nasdaq: CERS) and Shandong Zhongbaokang Medical Implements Co. Ltd. (ZBK) today announced that they are forming a joint venture (JV) with the intent to develop, obtain regulatory approval for, manufacture and commercialize the INTERCEPT Blood System for platelets and red blood cells in China.
  • The JV, which will be named Cerus ZBK Biomedical (CEZB), will be headquartered in Zibo, Shandong Province in eastern China.
  • The healthcare system in China continues to grow at a rapid pace, enabling expanded access to blood components expected to benefit from pathogen inactivation.
  • Additionally, Cerus will contribute an exclusive license to the INTERCEPT Blood System for platelets and red blood cells for CEZB to market across China.